Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285798 · ClinicalTrials.gov registry record · Phase 3
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
NCT07285798: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT07285798 is a Phase 3 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 176 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07285798, a Phase 3 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
Interventions
- DRUG KarXT
- DRUG KarX-EC
- DRUG KarXT + KarX-EC Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2026-09-11 |
| Est. Completion | 2029-08-04 |
| Phase | Phase 3 |
What is known before NCT07285798 opens enrollment
NCT07285798 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which KarXT is the first listed.
NCT07285798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07285798 about?
NCT07285798 is a clinical study titled "A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder". The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
What is the current status of trial NCT07285798?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2026-09-11. Estimated completion is 2029-08-04.
What interventions are being tested in trial NCT07285798?
The interventions under investigation include: KarXT (DRUG), KarX-EC (DRUG), KarXT + KarX-EC Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT07285798?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07285798's enrollment target sits among peer trials
176 1438th of 2000 higher than 561 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI